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Current antiretroviral therapy is effective in suppressing but not eliminating HIV-1 infection. Understanding the source
of viral persistence is essential for developing strategies to eradicate HIV-1 infection. We therefore investigated the
level of plasma HIV-1 RNA in patients with viremia suppressed to less than 50–75 copies/ml on standard protease
inhibitor- or non-nucleoside reverse transcriptase inhibitor-containing antiretroviral therapy using a new, real-time
PCR-based assay for HIV-1 RNA with a limit of detection of one copy of HIV-1 RNA. Single copy assay results revealed
that .80% of patients on initial antiretroviral therapy for 60 wk had persistent viremia of one copy/ml or more with an
overall median of 3.1 copies/ml. The level of viremia correlated with pretherapy plasma HIV-1 RNA but not with the
specific treatment regimen. Longitudinal studies revealed no significant decline in the level of viremia between 60 and
110 wk of suppressive antiretroviral therapy. These data suggest that the persistent viremia on current antiretroviral
therapy is derived, at least in part, from long-lived cells that are infected prior to initiation of therapy.
Citation: Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, et al. (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS
Pathog 3(4): e46. doi:10.1371/journal.ppat.0030046
Introduction
Infection with HIV-1 results in progressive immunodeﬁ-
ciency and death from opportunistic infection or cancer.
Current antiretroviral therapy is effective in suppressing
plasma viremia to levels below the detection limit of FDA-
approved assays (50–75 copies HIV-1 RNA/ml), restoring
immune function, and reducing morbidity and mortality.
Antiretroviral therapy does not cure HIV-1 infection,
however, and, at a minimum, eradication of HIV-1 infection
will require complete suppression of its replication as well as
elimination of latent viral reservoirs. Although some reports
have shown the persistence of low-level viremia in patients on
suppressive therapy [1–6], the determinants of this viremia,
and whether it results from ongoing replication cycles or
release from latent reservoirs, are not well deﬁned [2,7–9] due
in part to the limited sensitivity of prior HIV-1 RNA assays.
To investigate these issues, we developed a real-time PCR-
based method (single-copy assay, SCA) capable of detecting
and reliably quantifying HIV-1 RNA with a limit of one copy
per ml plasma [10]. Using this assay, we have found that more
than 80% of patients on currently recommended antiretro-
viral therapies have quantiﬁable viremia for at least 2 y after
initiation of therapy. These results have important implica-
tions for understanding the mechanism of HIV-1 persistence
despite long-term antiretroviral therapy.
Results/Discussion
We ﬁrst measured plasma HIV-1 RNA with both an FDA-
approved assay (bDNA; detection limit 75 copies/ml) and SCA
in three patients initiating antiretroviral therapy. As ex-
pected [11–13], therapy produced a rapid decline in plasma
HIV-1 RNA (Figure 1), reaching undetectable levels within
50–260 d. HIV-1 RNA values from the two assays were similar
at levels that were detectable by both assays, but the SCA
continued to detect HIV-1 RNA throughout the sampling
period, well below the limit of detection of the bDNA assay.
These initial observations suggested that low-level viremia
can persist for years in patients receiving suppressive
antiretroviral therapy. To investigate this phenomenon in a
larger patient population and to compare the effects of
different treatment regimens, we analyzed specimens from
study M98–863, a Phase III randomized clinical trial compar-
ing lopinavir/ritonavir (LPV/r) and nelﬁnavir (NFV), each in
combination with stavudine and lamivudine, in previously
antiretroviral-naı ¨ve HIV-1-infected individuals [14]. We
studied a subset of 145 patients (see Figure S1) whose plasma
HIV-1 RNA declined to less than 50 copies/ml within 24 wk of
initiating therapy and remained at this level at all time points
through 60 wk. SCA results were available from 130 patients
(63 on LPV/r and 67 on NFV). As shown in Figure 2, HIV-1
RNA values at week 60 in the two arms combined ranged
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3.2 (3.1) copies/ml and with no signiﬁcant between-arm
differences in the mean (p ¼ 0.56) or overall distribution of
values (p ¼ 0.82). Plasma HIV-1 RNA was below the limit of
quantiﬁcation by SCA in about 17% of patients (LPV/r arm:
17%; NFV arm: 18%).
We also determined the distribution of HIV-1 RNA levels
in 28 patients enrolled in National Institutes of Health (NIH)
studies whose viremia was suppressed to ,75 copies/ml on
non-nucleoside reverse transriptase inhibitor (NNRTI)-con-
taining regimens. As shown in Figure 2, the distribution of
SCA values from these patients was comparable to that of
patients in the M98–863 trial (p¼0.22); speciﬁcally, the mean
values were not signiﬁcantly different (p¼0.17) and there was
no difference between efavirenz- and nevirapine-containing
regimens (p ¼ 0.29).
We investigated virologic, immunologic, demographic, and
clinical parameters for correlates of persistent viremia in
samples from both arms of the M98–863 trial. Comparison of
the HIV-1 RNA level by SCA at week 60 to pretherapy RNA
levels (Figure 3) showed a signiﬁcant correlation (p , 0.001)
and a median decrease between pretherapy and week 60 HIV-
1 RNA values of 14,250-fold (range 448- to1,720,000-fold).
The correlation coefﬁcient (r
2 ¼ 0.17) suggests pretherapy
viral RNA level accounts for 17% of the variability in stable
viremia on therapy, and that other factors, such as time since
infection, may contribute to the level of on-therapy viremia.
No signiﬁcant differences between treatment arms were
detected in median HIV-1 RNA reduction, and additional
analyses (unpublished data) indicated that both the magni-
tude of HIV-1 RNA reduction and the level of persistent
viremia were not associated with pretherapy CD4þ T-cell
count, change in CD4þ T-cell count on therapy, age at
enrollment, or gender.
To examine the stability of the low level of viremia in the
M98–863 study, we next performed a longitudinal analysis of
HIV-1 RNA after week 60. Of the 145 patients with
pretherapy samples who had suppression of plasma HIV-1
RNA between weeks 24 and 60, 117 had samples available and
continuous suppression (all values ,50 copies/ml, Figure S1)
at subsequent time points. Results of SCA testing of one to
ﬁve samples (median of three) from each of these patients
during weeks 60–110 of therapy are shown in Figure 4. No
signiﬁcant decreases in HIV-1 RNA levels were detected over
time, regardless of whether patients were analyzed overall or
separately by treatment group; i.e., the HIV-1 RNA slopes
were not signiﬁcantly different from 0 overall or in either
treatment group. Among all patients combined, a half-life of
less than 67 wk could be excluded with 95% conﬁdence, using
a mixed model linear regression analysis.
The study presented here represents the ﬁrst large-scale
and long-term analysis of persistent viremia in patients on
standard antiretroviral therapy. Residual viremia on therapy
(median viral RNA of 3.1 copies/ml plasma) was more than 10-
fold below the limit of detection of FDA-approved HIV-1
RNA assays. Viremia was suppressed to less than 0.6 copies/ml
in approximately one-ﬁfth of patients, nearly 100-fold lower
than the detection limit of FDA-approved assays. As such,
SCA permitted a more accurate estimate of the maximal
effect of antiretroviral therapy. Comparison of pre- and post-
therapy levels revealed a median reduction in HIV-1 RNA of
more than 14,000-fold. After this maximal reduction in
viremia occurred, however, HIV-1 RNA levels remained
stable with no signiﬁcant decline between the ﬁrst and
second years of therapy.
In previous studies, investigators using smaller datasets
have reported slow declines in plasma HIV-1 RNA corre-
sponding to half-lives of infected cells of 6 mo [1,6] or longer
[8,15]. Our longitudinal analysis, using a much larger dataset,
revealed no signiﬁcant evidence of decline of HIV-1 RNA
levels between 60 and 110 wk of therapy. It is possible,
however, that a slow decline in HIV-1 RNA with half-life of
greater than 67 wk could have been missed with the current
dataset. We are currently assembling a new set of samples
with longer follow-up to investigate this possibility.
Three sources of persistent viremia have been proposed: (i)
ongoing cycles of viral replication in the presence of
antiretroviral drugs because of inadequate drug inhibitory
potency; (ii) production of HIV-1 from sanctuary sites into
which antiretrovirals do not penetrate sufﬁciently; or (iii)
reservoirs of long-lived cells infected prior to the initiation of
therapy with production of HIV-1 from integrated provi-
ruses, but without complete cycles of replication occurring
because of blockade by antiretroviral drugs [8,15–17]. The
marked stability of viremia detected in this study, in addition
to the similar levels of suppression by LPV/r-, NFV-, or
NNRTI-containing regimens, strongly suggests that current
antiretroviral therapies inhibit HIV-1 replication cycles and
virus production to below a background level set by virus
released from long-lived cells. More speciﬁcally, the residual
viremia is likely derived from a reservoir of long-lived cells
infected before the initiation of therapy. This reservoir might
comprise chronically infected cells that produce virus at a low
stable rate and/or latently-infected cells, like resting CD4þ T
cells, that can be isolated from infected individuals on
suppressive therapy and activated to produce infectious virus
[8,15,18,19]. Our data describe only the level of viremia, not
other viral characteristics. Others have reported no accumu-
lation of new resistance mutations and little genetic variation
over time in patients with suppressed viremia. Recent
analyses have suggested that a limited number of genetic
variants circulate during suppression [20–22], also consistent
with a model of HIV-1 production from long-lived cells.
Analyses of HIV-1 replication during suppressive antiretro-
viral therapy intended to distinguish between active repli-
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Author Summary
Combination antiretroviral therapy is effective in reducing, but not
eliminating, HIV-1 replication. Residual viremia during suppressive
antiretroviral therapy may arise from a number of sources, including
reservoirs of long-lived virus-producing cells, or ongoing complete
cycles of viral replication. Here, we used a new, more sensitive assay
of HIV-1 RNA to measure residual viremia in a large cohort of
patients with prolonged suppression on antiretroviral therapy. We
found a persistent, stable level of viremia in patients on prolonged
therapy that correlated with pretherapy levels of HIV-1. Over 80% of
patients had viremia  1 copy/ml plasma, and the level of viremia
was independent of the drug regimen patients were taking. These
data strongly suggest that persistent viremia on antiretroviral
therapy is likely derived from reservoirs of long-lived virus-
producing cells that are not affected by currently available drugs
that target new cycles of viral replication. New antiviral strategies
that eradicate this reservoir will be necessary to cure HIV-1 infection.cation cycles and production from reservoirs have yielded
conﬂicting results [6,23,24], and additional treatment inten-
siﬁcation trials to distinguish these possibilities are underway
(NIH study 02-I-0232, http://clinicalstudies.info.nih.gov/cgi/
protinstitute.cgi?NIAID.0.html). Information from such trials
is essential in designing future antiretroviral strategies to
fully suppress viremia.
This study analyzed only those participants in the M98–863
study whose viremia remained suppressed to ,50 copies/ml
for 60–110 wk. As demonstrated in prior intent-to-treat
analyses of M98–863, LPV/r had superior efﬁcacy compared
to NFV as judged by Kaplan-Meier analysis of plasma HIV-1
RNA rebound to greater than 400 copies/ml through 96 wk
[14,25–27]. The present results imply that the difference in
efﬁcacy is not associated with differences in residual viremia
in the two groups. Early therapeutic failures have been
hypothesized to result from the emergence of mutations that
exist prior to initiation of antiretroviral therapy [16,28]. In
this regard, the superiority of LPV/r may be related in part to
its contribution to a higher genetic barrier to resistance for
the combination regimen, as compared to NFV, for which a
single mutation confers signiﬁcant resistance [29,30]. Other
factors that may have contributed to the differential efﬁcacy
observed between LPV/r and NFV are related to differences
in pharmacokinetic proﬁles, as lopinavir plasma concentra-
tions exceed the IC50 for wild-type HIV by a considerably
greater margin than observed with NFV. Consequently,
individual pharmacokinetic variability and adherence lapses
may be more likely to result in loss of suppression with NFV-
based regimens compared to LPV/r-based therapy. Similar
levels of persistent viremia in patients undergoing NNRTI-
containing therapy for prolonged periods (mean ¼ 111.2 wk)
were noted even though the genetic barrier to NNRTI is likely
to be low; again, early drug failures due to pre-existing
mutations were likely excluded from selection. The presence
of persistent viremia has a number of important implications
for development and application of antiretroviral therapies.
Few patients on antiretroviral therapy have ‘‘undetectable’’
viremia if sufﬁciently sensitive assays are employed, and
Figure 1. Decline and Stable Persistence of Plasma HIV-1 RNA in Patients
Suppressed on Antiretroviral Therapy
Plasma from patients initiating antiretroviral therapy with stavudine þ
lamivudine þ efavirenz (patients A and B) or stavudine þ lamivudine þ
indinavirþnevirapine (patient C) was assayed by bDNA (diamonds) and
SCA (squares). Levels of virus above the limit of detection for each assay
are shown by filled symbols; levels below this limit are shown by hollow
symbols plotted at the assay limit.
doi:10.1371/journal.ppat.0030046.g001
Figure 2. Distribution of Plasma HIV-1 RNA Levels in Patients with
Persistently Suppressed Viremia (HIV-1 RNA ,50 Copies/ml from Week
24 to 60) on Standard Antiretroviral Therapy
Week 60 viral RNA levels for M98–863 patients on LPV/r- (blue) or NFV-
containing (red) regimens were determined by SCA. The percentile of
patients in each group with a given RNA level is presented. SCA
determinations for patients on NNRTI- containing regimens (n ¼ 28) for
.1 y are included (green). The inset shows the mean and median log10
RNA levels for each group.
doi:10.1371/journal.ppat.0030046.g002
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Source of Stable HIV-1 Viremia on ARTgreater suppression of viremia can probably not be achieved
using current inhibitors of HIV-1 replication because
persistent viremia likely arises, at least in part, from chroni-
cally infected cells. New therapeutic strategies will be needed
to eliminate persistent viremia and its source.
Materials and Methods
Research participants. Plasma samples were obtained from stored
specimens from patients with plasma HIV-1 RNA ,50 copies/ml in
the M98–863 trial and from patients on treatment at the NIH Clinical
Center as follows.
M98–863 patients. M98–863 was a randomized double-blind, Phase
III study comparing LPV/r (400/100 mg twice daily) (n¼326) with NFV
(750 mg three times daily or 1,250 mg twice daily) (n ¼ 327), each in
combination with stavudine and lamivudine, in previously antire-
troviral-naı ¨ve HIV-1-infected patients [14]. All patients in M98–863
who achieved plasma HIV-1 RNA values ,50 copies/ml by week 24 of
therapy and who remained undetectable at that level at all study visits
through week 60 of follow-up were identiﬁed for analysis (n ¼ 237).
From this group, a subset of 163 participants treated at investiga-
tional sites in North America was identiﬁed for SCA testing. Of these,
six were excluded for lack of archived samples and 12 for inefﬁcient
ampliﬁcation of baseline sample. Pretherapy samples of 145
participants were ampliﬁable by SCA (Figure S1), and only these
participants were candidates for further analyses. Of these, 130 also
had valid assay results for week 60 samples and constituted the week
60 group analysis. All 145 participants with ampliﬁable pretherapy
samples who remained on study and maintained suppressed plasma
HIV-1 RNA levels ,50 copies/ml through 110 wk of follow-up were
considered for longitudinal analysis. As shown in Figure S1, six
participants did not have samples available after week 60; 21 did not
maintain complete suppression after week 60 by conventional viral
RNA testing; and one had no valid assay results during analysis.
Therefore, 117 participants were included in the longitudinal
analysis.
Prior to participation in the study, all M98–863 patients provided
informed consent for viral RNA quantitation. The protocols and
procedures for subsequent SCA analysis of these samples by the HIV
Drug Resistance Program were reviewed and approved by the NIAID
IRB.
Patients taking NNRTI-containing regimens. Patients taking
NNRTI-containing regimens with suppressed plasma HIV-1 RNA
levels by FDA-approved testing were also recruited from treatment
studies performed at the NIH Clinical Center (n ¼ 28). All patients
were taking Department of Health and Human Services (DHHS)
guideline-approved antiretroviral regimens containing efavirenz (n¼
22) or nevirapine (n¼6) and were either sampled frequently by bDNA
or SCA following initiation of therapy or had been on therapy for 20
to .250 wk (mean 111.2 wk) prior to SCA sampling. All patients were
well and without history of recent intercurrent illness at the time of
phlebotomy, had hemoglobin levels  12 g/dl, and provided informed
consent for phlebotomy and for research sample storage.
HIV-1 RNA determination. The SCA for HIV-1 RNA detection was
performed as described previously [10], starting with 7 ml plasma,
except for the M98–863 samples, from which only 3 ml plasma was
available. As a result, the lower limit of quantitation for these samples
was 0.6 copies HIV-1 RNA/ml, compared to 0.3 copies/ml when 7 ml
plasma was used. In all analyses, values below the assay quantitation
limit for study M98–863 (0.6 copies/mL) were considered to be equal
to the assay limit. Plasma was obtained from whole blood samples
within 2–4 h of phlebotomy and immediately frozen at 70 8C. [10,31].
For each sample, three separate aliquots of the cDNA product were
assayed for HIV-1 RNA and two aliquots for the recombinant avian
retrovirus internal standard RNA using real-time PCR of conserved
sequences within gag as described [10]. About 10% of M98–863
patients were excluded because SCA and Amplicor assays on
pretherapy samples were signiﬁcantly discordant due to inefﬁcient
ampliﬁcation by SCA (Figure S2), probably a result of polymorphism
in the probe or primer sequences (A. Wiegand and S. Palmer,
unpublished data). In all other samples, there was a close correlation
between commercial Amplicor RT-PCR and SCA values for prether-
apy samples (r
2 ¼ 0.61, Figure S2). Further details of extraction,
optimum ampliﬁcation conditions, and performance characteristics,
as well as quality control procedures to prevent artifactual
ampliﬁcation, have been described [10].
Study M98–863 used the PCR-based Amplicor HIV-1 MONITOR
assay version 1.0 for plasma HIV-1 RNA quantitation, performed
according to manufacturer’s speciﬁcations (Roche Diagnostics, http://
www.roche.com). For patients taking NNRTI-containing regimens,
plasma HIV-1 RNA was quantiﬁed using the bDNA-based VERSANT
HIV-1 RNA assay version 3.0 according to manufacturer’s speciﬁca-
tions (Bayer Diagnostics, http://diagnostics.siemens.com) in a manu-
facturer-certiﬁed site using the semiautomated Bayer System 340
unit. Versant HIV-1 RNA version 3.0 is approved by the FDA for
clinical use with a limit of quantiﬁcation of 75 copies HIV-1 RNA/ml
plasma, although our reported experience with this assay indicates a
quantiﬁcation limit of 50 copies/ml [32,33].
Statistical analysis. For log-transformed baseline viral RNA
determinations, comparisons between Amplicor HIV-1 RNA assays
and SCA were conducted using linear regression and Pearson’s
correlation, as were comparisons between log-transformed viral RNA
determinations at baseline and week 60. Mean SCA values were
compared between groups using a one-way analysis of variance;
comparisons of distributions of SCA values were conducted using the
Figure 3. Correlation between Pretherapy and On-Therapy Viral RNA
Levels
Pretherapy and week 60 SCA values were determined for 130 patients
from both the NFV and LPV/r arms in M98–863. Correlation coefficients
for patients taking LPV/r and NFV regimens were similar.
doi:10.1371/journal.ppat.0030046.g003
Figure 4. HIV-1 RNA Levels Over 50 wk of Suppressive Antiretroviral
Therapy
Plasma samples from patients in both arms of the M98–863 trial with
viremia suppressed to ,50 copies/ml during weeks 60–110 were
subjected to SCA analysis. HIV-1 RNA levels for each patient are
presented here as a function of weeks on therapy.
doi:10.1371/journal.ppat.0030046.g004
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Source of Stable HIV-1 Viremia on ARTKolmogorov-Smirnov test. A linear mixed effects regression model
with a spatial linear correlation structure to account for correlation
between repeated measurements within participants was used to
assess the relationship between time and log-transformed viral
determinations using SCA. In all analyses, values below the assay
quantitation limit for study M98–863 (0.6 copies/mL) were considered
to be equal to the assay limit. Sensitivity analyses using other
imputation methods did not alter results meaningfully.
Supporting Information
Figure S1. Schematic Describing Patient Inclusion for Study of HIV-1
Viremia in M98–863 Patients
Found at doi:10.1371/journal.ppat.0030046.sg001 (21 KB DOC).
Figure S2. Correlation between Pretherapy Plasma HIV-1 RNA Levels
as Determined by Amplicor HIV-1 Monitor Assay and SCA
Pretherapy samples from 157 participants were analyzed by both
assays. 12 samples (triangles) had SCA values signiﬁcantly lower than
Amplicor and were excluded from further analysis. Remaining
samples (n¼145, diamonds) were highly correlated (r
2¼0.61, broken
lines represent 6 0.5 log10 copies/mL from Y¼X line); corresponding
participants were included in subsequent analyses.
Found at doi:10.1371/journal.ppat.0030046.sg002 (32 KB PDF).
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